| spelling |
Análise de fator de necrose tumoral e deus receptores em soro e líquido intracístico em neoplasias de ovárioTNF-alfa.sTNF-R1.sTNF-R2.Tumor de ovário.Fatores prognósticos.TNF-alpha.sTNF-R1.sTNF-R2.Ovarian tumor.Prognostic factors.Ginecologia e ObstetríciaINTRODUÇÃO: O câncer de ovário é um grande desafio para oncologistas ginecológicos. Apesar de uma vasta quantidade de pesquisa clínica e laboratorial, melhoria nas técnicas cirúrgicas e um arsenal cada vez maior de agentes quimioterápicos, o câncer de ovário ainda permanece sendo a malignidade ginecológica mais letal e uma das principais causas de morbidade para a maioria daquelas que sofrem com a doença. Há uma necessidade importante do desenvolvimento de novos biomarcadores de diagnóstico e prognóstico dessa neoplasia, que podem também servir como alvos de novas modalidades terapêuticas. OBJETIVOS: Os objetivos do estudo foram comparar a dosagem de TNF-α e de seus receptores solúveis (sTNF-1R1 e sTNF-R2) no soro e líquido intracístico entre o grupo de neoplasias benignas e o de neoplasias malignas primárias de ovário; relacionar a dosagem de TNF-α, sTNF-1R1 e sTNF-R2 no soro e no líquido intracístico de pacientes com neoplasia maligna de ovário com fatores prognósticos clínicos e patológicos. MATERIAL E MÉTODOS: Sessenta e três pacientes foram avaliadas no Ambulatório de Massa Pélvica da Universidade Federal do Triângulo Mineiro (UFTM) e submetidas à cirurgia de acordo com critérios pré-determinados, sendo 17 neoplasias malignas e 46 neoplasias benignas. A quantificação de TNF-α e de seus receptores solúveis sTNF-R1 e sTNF-R2 no soro e no líquido intracístico foi realizada pelo método ELISA. A coleta do soro foi realizada no pré- operatório. Os dados foram analisados estatisticamente. Os resultados foram expressos em medianas e percentis. Os resultados entre os grupos não pareados (neoplasias benignas e malignas) foram comparados através de teste Mann-Whitney. As diferenças foram consideradas significativas para p<0,05.RESULTADOS: A dosagem de TNF-R2 intracístico foi significativamente mais alta nas neoplasias malignas quando comparado com as neoplasias benignas (p=0.0235). Não houve significância estatística nas comparações de TNF e TNF-R1 no líquido intracístico, e nem nas dosagens séricas. Na avaliação dos fatores prognósticos, valores maiores de TNFR2 intracístico estiveram relacionados a câncer de ovário tipo II com tendência à significância (p=0.0823). Valores maiores de TNFR2 intracístico estiveram relacionados a graus de diferenciação 2 e 3 (p=0.0087). Não houve significância estatística na avaliação ao estadiamento. CONCLUSÃO: A dosagem de TNF-R2 intracístico é mais alta em neoplasias malignas quando comparado com as neoplasias benignas de ovário. Além disso, valores maiores de TNFR2 intracístico estiveram relacionados a câncer de ovário tipo II e a graus de diferenciação 2 e 3, o que sugere que esse receptor solúvel pode ser um potencial marcador de mau prognóstico em câncer de ovário, podendo alvo de futuras pesquisas de terapias-alvo seletivas anti-TNFR2.INTRODUCTION: Ovarian cancer is a major challenge for gynecological oncologists. Despite a vast amount of clinical and laboratory research, improvement in surgical techniques and an increasing array of chemotherapeutic agents, ovarian cancer still remains the most lethal gynecological malignancy and a leading cause of morbidity for the majority of those suffering with the disease. There is an important need for the development of new biomarkers for the diagnosis and prognosis of this neoplasia, which may also serve as targets for new therapeutic modalities. OBJECTIVES: The objectives of the study are to compare the dosage of TNF-α and its soluble receptors (sTNF-1R1 and sTNF-R2) in the serum and intracellular fluid between the group of benign neoplasms and that of primary ovarian malignancies and to relate the dosage of TNF-α, sTNF-1R1 and sTNF-R2 in serum and intracellular fluid of patients with malignant ovarian neoplasia with clinical and pathological prognostic factors. MATERIALS E METHODS: Sixty three patients were evaluated at the Pelvic Mass Ambulatory of the Federal University of the Triângulo Mineiro (UFTM) and submitted to surgery according to predetermined criteria, 17 malignant neoplasms and 46 benign neoplasms. Quantification of TNF-α and its soluble sTNF-R1 and sTNF-R2 receptors in serum and intracellular fluid was performed by the ELISA method. Serum collection was performed preoperatively. The data were analyzed statistically. The results were expressed in medians and percentiles. Results between the unpaired groups (benign and malignant neoplasms) were compared by Mann-Whitney test. The evaluation of prognostic factors was performed using the chi-square test, with significance level lower than 0.05. The differences were considered significant at p <0.05.RESULTS: Intracystic TNF-R2 levels were significantly higher in malignant neoplasms compared to benign neoplasms (p = 0.0235). There was no statistical significance in the comparisons of TNF and TNF-R1 in the intracellular fluid, nor in serum dosages. In the evaluation of prognostic factors, higher intracystic TNFR2 values were related to type II ovarian cancer with a tendency to significance (p = 0.0823). Higher intracystic TNFR2 values were related to degrees of differentiation 2 and 3 (p = 0.0087). Statistical evaluation was not statistically significant.Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorConselho Nacional de Desenvolvimento Científico e TecnológicoFundação de Amparo à Pesquisa do Estado de Minas GeraisUniversidade Federal do Triângulo MineiroInstituto de Ciências da Saúde - ICS::Programa de Pós-Graduação em Ciências da SaúdeBrasilUFTMPrograma de Pós-Graduação em Ciências da SaúdeNOMELINI, Rosekeila Simões03651235602http://lattes.cnpq.br/0564643325267326MURTA, Eddie Fernando Cândido47668032649http://lattes.cnpq.br/5724192420139830BORGES JÚNIOR, Luciano Eliziário2019-11-14T12:24:37Z2017-04-25info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfapplication/pdfBORGES JÚNIOR, Luciano Eliziário. Análise de fator de necrose tumoral e deus receptores em soro e líquido intracístico em neoplasias de ovário. 2017. 85f. Dissertação (Mestrado em Ciências da Saúde) - Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Triângulo Mineiro, Uberaba, 2019.http://bdtd.uftm.edu.br/handle/tede/910porA.C.CAMARGO CANCER CENTER. Manual de Condutas em Ginecologia Oncológica / A.C.Camargo Cancer Center, Departamento de Ginecologia. 2 ed.- São Paulo: FAP; 2014. AGGARWAL BB. Comparative analysis of the structure and function of TNF-alpha and TNFbeta. Immunol Ser. 1992;56:61-78. AGARWAL, R.; KAYE, S. B. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol, v. 16, n. 1, p. 4-6, 2005. ALMEIDA, J.R.C. Farmacêuticos em oncologia: uma nova realidade. 1ª ed. São Paulo: Atheneu. 2004. 61-72p ALQASEMI, U.; KUMAVOR, P.; AGUIRRE, A.; ZHU, Q. Recognition algorithm for assisting ovarian cancer diagnosis from coregistered ultrasound and photoacousticimages: ex vivo study. Journal of Biomedical Optics. v.17, n.12, p.1-10, 2012. AMERICAN CANCER SOCIETY. CANCER FACTS & FIGURES 2013. Disponível em: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ACSPC-036845 AMERICAN CANCER SOCIETY. Cancer Facts & Figures 2015. Atlanta, GA, 2015. Disponível em<http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/>.Acesso em: 26 de janeiro de 2015. ATHANASSIADOU, P.; GRAPSA, D.; ATHANASSIADES, P.; GONIDI, M.; ATHANASSIADOU, A.M.; TSIPIS, A.; PATSOURIS, E. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204(4):241-9. Epub 2008 Jan 2. BAERT, T.; TIMMERMAN, D.; VERGOTE, I.; COOSEMANS, A. Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts, Views & Vision in ObGyn. v.7, n.1, p.67-72, 2015. BALKWILL, F. Tumor necrosis factor or tumor promoting factor: Cytokine Growth Factor Rev, v. 13, n. 2, p. 135–141, 2002. BALKWILL F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-16. BELL DA, LONGACRE TA, PRAT J, KOHN EC, SOSLOW RA, ELLENSON LH, MALPICA A, STOLER MH, KURMAN RJ. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004 Aug;35(8):934-48. BERTAZZA, L.; MOCELLIN, S. Tumor necrosis factor (TNF) biology and cell death. Front Biosci, v. 13, p. 2736-2743, 2008. CHARLES, K. A. et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest, v. 119, n. 10, p. 3011–3023, 2009. CHERCHI, P.L.; CAPOBIANCO, G.; AMBROSINI, G. et al. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology. European journal of gynaecological oncology. v.23, n.2, p.163-165, 2002. CHOBANIAN, N.; DIETRICH, C.S. Ovarian cancer. Surgical Clinics North America. v.88, n.2, 285-299, 2008. CIANFRANI T: “A short history of obstetrics and gynecology.” Springfield, IL: CC Thomas; 1960. COOSEMANS, A.; BAERT, T.; VERGOTE, I. A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts, Views & Vision in ObGyn. v.7, n.1, p.73-78, 2015. DALY M, OBRAMS GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol. 1998 Jun;25(3):255-64. Review. DOBRZYCKA, B; TERLIKOWSKI, SJ; KOWALCZUK, O; KINALSKI, M. Circulating levels of TNF-α and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur. Cytokine Netw., Vol. 20 n° 3, September 2009, 131-4. DONG HP, KLEINBERG L, SILINS I, FLØRENES VA, TROPÉ CG, RISBERG B, NESLAND JM, DAVIDSON B. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer. 2008 Jan 1;112(1):84-93. DUMITRU CA, LANG S, BRANDAU S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013 Jun;23(3):141-8. EDGELL, T.; MARTIN-ROUSSETY, G.; BARKER, G. et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. Journal of Cancer Research and Clinical Oncology. v.136, n.7, p.1079-1088, 2010. FATHALLA, M. F. Incessant ovulation: a factor in ovarian neoplasia? Lancet, v. 2, m. 7716, p. 163, 1971. FEHM, T.; NEUBAUER, H.; BRÄUTIGAM, K. et al. Diagnostik undtherapie des ovarialkarzinoms. Innovative techniken. Der Gynäkologe. v.43, n.7, p.586-594, 2010. FERREIRA PA, SALLUM LF, SARIAN LO, ANDRADE LA, DERCHAIN S. [Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis]. Rev Bras Ginecol Obstet. 2012 May;34(5):196-202. FISHMAN, D.; COHEN, L.; BLANK, S.V. et al. The role of ultrasound evaluationin the detection of early-stage epithelial ovarian cancer. American Journal of Obstetrics & Gynecology. v.192, n.4, p.1214-1221, 2005. GAYTHER, S. A.; RUSSELL, P.; HARRINGTON, P. et al. The contribution ofgermline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for otherovarian cancer-susceptibility genes. American Journal of Human Genetics. v.65, n.4, p.1021-1029, 1999. GIUNTOLI RL 2ND, WEBB TJ, ZOSO A, ROGERS O, DIAZ-MONTES TP, BRISTOW RE, OELKE M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009 Aug;29(8):2875-84. GOTO, N. et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol, v. 77, n. 3, p. 217-225, 2006. GOVINDARAJ C, SCALZO-INGUANTI K, MADONDO M, HALLO J, FLANAGAN K, QUINN M, PLEBANSKI M. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol. 2013 Oct;149(1):97- 110. doi: 10.1016/j.clim.2013.07.003. Epub 2013 Jul 25. GUERRIERO S, AJOSSA S, GARAU N, PIRAS B, PAOLETTI AM, MELIS GB. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol. 2005 Feb;192(2):401-6. GUNDOGDU F, SOYLU F, ERKAN L, TATLI O, MAVI S, YAVUZCAN A. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Archives of Gynecology and Obstetrics. June 2011, Volume 283, Issue 6, pp 1397– 1402 GUPTA M, BABIC A, BECK AH, TERRY K. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 2016 Aug;54:82-91. doi: 10.1016/j.humpath.2016.03.006. Epub 2016 Apr 8. HORIUCHI, A.; ITOH, K.; SHIMIZU, M. et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecologic Oncology. v.88, n.3, p.309-317, 2003 INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. Estimativa 2014: incidência de câncer no Brasil. Disponível em:< http:// http://www.inca.gov.br/estimativa/2014/sintese-de-resultados-comentarios.asp>. Acesso em: 6 fev. 2016. INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. Disponível em http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/ovario. Acesso em: 9 nov. 2016. JAMMAL MP, MARTINS-FILHO A, SILVEIRA TP, MURTA EF, NOMELINI RS. Cytokines and Prognostic Factors in Epithelial Ovarian Cancer. Clin Med Insights Oncol. 2016 Aug 2;10:71-6. doi: 10.4137/CMO.S38333. eCollection 2016. KEHOE S, POWELL J, WILSON S, WOODMAN C. The influence of the operating surgeon's specialization on patients survival in ovarian carcinoma. Br J Cancer 1994;70:1014-7. KOUKLAKIS, G. et al. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther, v. 7, p. 195-199, 2013. KNUTSON, K.L.; CURIEL, T.J.; SALAZAR, L.; DISIS, M.L. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/oncology clinics of North America. v.17, n.4, p.1051-1073, 2003 KOLOMEYEVSKAYA N, ENG KH, KHAN AN, GRZANKOWSKI KS, SINGEL KL, MOYSICH K, SEGAL BH. . Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015 Aug;138(2):352-7. doi: 10.1016/j.ygyno.2015.05.009. Epub 2015 May 20. KULBE H, THOMPSON R, WILSON JL, ROBINSON S, HAGEMANN T, FATAH R, GOULD D, AYHAN A, BALKWILL F. The inflammatory cytokine tumor necrosis factoralpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007 Jan 15;67(2):585-92. KURMAN, R. J.; SHIH, Ie-Ming. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, v. 34, n. 3, p. 433-443, 2010. KURMAN, R. J.; SHIH, Ie-Ming. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Human Pathology, v. 42, n. 7, p. 918–931, 2011. MANTOVANI, A. Cancer: inflammation by remote control. Nature, v. 435, v. 7043, p. 752– 753, 2005. MARSDEN DE., FRIEDLANDER M.: Current Management of Epithelial Ovarian Carcinoma: A Review. Seminars in Surgical Oncology 2000; 19:11–19. MARTINS FILHO A, JAMMAL MP, CÔBO EDE C, SILVEIRA TP, ADAD SJ, MURTA EF, NOMELINI RS. Correlation of cytokines and inducible nitric oxide synthase expression with prognostic factors in ovarian cancer. Immunol Lett. 2014 Mar-Apr;158(1-2):195-9. doi: 10.1016/j.imlet.2014.01.005. Epub 2014 Jan 18. MAYER AR, CHAMBERS SK, GRAVES E, HOLM C, TSENG PC, NELSON BE, et al. Ovarian cancer staging: does it require a gynecological oncologist? GynecolOncol 1992;47:223-7. MIELCZAREK-PALACZ, A.; KONDERA-ANASZ, Z.; SIKORA, J. Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours. Arch Med Sci, v. 8, n. 5, p. 848-853, 2012. MINARETZIS D, TSIONOU C, TZIORTZIOTIS D, MICHALAS S, ARAVANTINOS D. Ovarian tumors: prediction of the probability of malignancy by using patient’s age and tumor morphologic features with a logistic model. GynecolObstet Invest, 1994; 38: 140-4. MOORE, R.G.; MCMEEKIN, D.S.; BROWN, A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. v.112, n.1, p.40-46, 2009. MURTA, E.F.C.; ANDRADE, J.M.; BIGHETTI, S. Aspectos epidemiológicos do câncer de ovário. Jornal Brasileiro de Ginecologia. v.105, n.6, p.269-274, 1995. MURTA, E.F.; DA SILVA, C.S.; GOMES, R.A. et al. Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. European journal of gynaecological oncology.v.25, n.6, p.707-712, 2004. MURTA, E.F.; NOMELINI, R.S. Early diagnosis and predictors of malignancy of adnexal masses. Current opinion in obstetrics & gynecology. v.18, n.1, p.14-19, 2006. NARASIMHAN, K.; CHANGQING, Z.; CHOOLANI, M. Ovarian cancer proteomics: Many technologies one goal. Proteomics Clin Appl, v. 2, n. 2, p. 195-218, 2008. NUNES, N.; AMBLER, G.; FOO, X. et al. Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. Ultrasound in Obstetrics and Gynecology. v.44, n.5, p.503-514, 2014. OLIVIER, R.I.; LUBSEN-BRANDSMA, M.A.; VERHOEF, S.; VAN BEURDEN, M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecologic Oncology. v.100, n.1, p.20-26, 2006. OMURA GA, BRADY MF, HOMESLEY HD, YORDAN E, MAJOR FJ, BUCHSBAUM HJ, PARK RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991 Jul;9(7):1138-50. OPALA T, RZYMSKI P, WILCZAK M, WOŹNIAK J. Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients Eur J Gynaecol Oncol. 2005;26(1):43-6. OSMERS RGW, OSMERS M, VON MAYDELL B, WAGNER B, KUHN W. Evaluation of ovarian tumors in the post-menopause by transvaginosonography. Eur J ObstetGynecolReprodBiol, 1998; 77: 81-8. PADILLA, L. A.; RADOSEVICH, D. M.; MILAD, M. P. Limitations on the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet, v. 88, p. 84- 88, 2005. PIURA B1, MEDINA L, RABINOVICH A, DYOMIN V, LEVY RS, HULEIHEL M. Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-α in morphological changes of ovarian cancerous cells. Anticancer Res. 2014 Feb;34(2):745-52. PRIES R & WOLLENBERG B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006, 17: 141-6.[41] Aggarwal BB, Shishodia S, Sandur SK et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006, 72:1605–21. REIS, F.J.C. Rastreamento e diagnóstico das neoplasias de ovário - papel dos marcadores tumorais. Revista Brasileira de Ginecologia e Obstetrícia. v.27, n.4, p.222-227, 2005. RISCH, H.A.; MCLAUGHLIN, J.R.; COLE, D.E. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics. v.68, n.3, p.700-710, 2001. RIVOIRE, W. A. et al. Neoplasias de ovário e de trompa de Falópio. In: FREITAS, F.; MENKE, C.; RIVOIRE, W. A. Passos e Rotinas em Ginecologia. 5. ed. Porto Alegre: Ed Artmed, 2006, 362-384. ROTHE J, GEHR G, LOETSCHER H, LESSLAUER W. Tumor necrosis factor receptors-- structure and function. Immunol Res. 1992;11(2):81-90. RUBIN, S.C. Surgery for ovarian cancer. Hematology/Oncology Clinics of North America. v.6, n.4, p.851-865, 1992. SANKARANARAYANAN R, FERLAY J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207-25. SAMSAMI DEHAGHANI A, SHAHRIARY K, KASHEF MA et al. Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep. 2009 Nov;36(8):2393- 7. SASI SP, YAN X, ENDERLING H, PARK D, GILBERT HY, CURRY C, COLEMAN C, HLATKY L, QIN G, KISHORE R, GOUKASSIAN DA. Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene. 2012 Sep 13;31(37):4117-27. doi: 10.1038/onc.2011.567. Epub 2011 Dec 12. SCHMELER K.M., SUN C. C., BODURKA D. C., et al. Prophylactic bilateral salpingooophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 2006;108(3):515–20. SETHI, G.; SUNG, B.; AGGARWAL, B. B. TNF: a master switch for inflammation to cancer. Front Biosci, v. 13, p. 5094-5107, 2008. SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016. CA Cancer J Clin. 2016 JanFeb;66(1):7-30. SMITH, H. Clinical Management of Ovarian Cancer [book review]. N Engl J Med, v. 345, n. 2, p. 152-153, 2001. SOCIETY OF GYNECOLOGIC ONCOLOGISTS (SGO). Clinical practice committee estatement on prophylactic salpingo-oophorectomy. Gynecologic Oncology. v.98, n.2, p.179- 181, 2005. STAFF, A.C.; BOCK, A.J.; BECKER, C. et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecologic Oncology. v.118, n.3, 237-243, 2010 STEIN, R. C. & DALGLEISH, A. G. Immunomodulatory agents: the cytokines. Eur J Cancer, v. 30a, p. 400-404. 1994. SZLOSAREK, P. W. et al. Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer, v. 121, p. 6-11, 2007. SZPUREK D, MOSZYNIKI R, ZIETKOWIAK W, SPACZYNSKI M, SAJDAK S. An ultrasonographic morphological index for prediction of ovarian tumor malignancy. EurGynaecolOncol, 2005; 26: 51-4 TARTAGLIA LA, GOEDDEL DV. Two TNF receptors. Immunol Today. 1992 May;13(5):151-3. TAVARES-MURTA, B.M.; CUNHA, F.Q.; MIRANDA, R. et al. Differential tumor microenvironment in human ovarian cystic tumors. Tumori. v.90, n.5, p.491-497, 2004 TAVASSOLI, F. A.; DEVILEE, P. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003. TURETSKAYA RL, FASHENA SJ, PAUL NL, RUDDLE NH. Genomic structure, induction, and production of TNF-beta. Immunol Ser. 1992;56:35-60. VAN CALSTER, B.; VAN HOORDE, K.; VALENTIN, L. et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. British Medical Journal. v.349, n.g5920, p.1-14, 2014. WHITTEMORE, A.S.; HARRIS, R.; ITNYRE, J. Characteristics relating to ovarian câncer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epitelial ovarian cancers in white women. American Journal of Epidemiology. v.136, n.10, p.1184-1203, 1992. WHITTEMORE AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994;55(3 Pt 2):S15-9. WOODRUFF J.D. The pathogenesis of ovarian neoplasia. Johns Hopkins Med J 1979;144:117–120. YAWN BP, WOLLAN P, KLEE M, BARRETTE B. Ovarian carcinoma: care and survival in a community-based population. Clin. Ther, 2001; 23: 146-59. YESILYURT H, TOKMAK A, GUZEL AI, SIMSEK HS, TERZIOGLU SG, ERKAYA S, GUNGOR T. Parameters for predicting granulosa cell tumor of the ovary: a single center retrospective comparative study. Asian Pac J Cancer Prev. 2014;15(19):8447-50. ZANETTA G, ROTA S, CHIARI S. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998. 9:1097- 101. ZEPPERNICK, F.; MEINHOLD-HEERLEIN, I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal câncer. Arch Gynecol Obstet, v. 290, p. 839–842, 2014 ZHANG, L.; CONEJO-GARCIA, J.R.; KATSAROS, D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine. v.348, n.3, 203-213,http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFTMinstname:Universidade Federal do Triangulo Mineiro (UFTM)instacron:UFTM2019-11-15T04:00:25Zoai:bdtd.uftm.edu.br:tede/910Biblioteca Digital de Teses e Dissertaçõeshttp://bdtd.uftm.edu.br/PUBhttp://bdtd.uftm.edu.br/oai/requestbdtd@uftm.edu.br||bdtd@uftm.edu.bropendoar:2024-04-24T09:59:04.301918Biblioteca Digital de Teses e Dissertações da UFTM - Universidade Federal do Triangulo Mineiro (UFTM)false
|